Perceptive Advisors LLC Sells 3,121,851 Shares of Palisade Bio, Inc. $PALI

Perceptive Advisors LLC lessened its position in shares of Palisade Bio, Inc. (NASDAQ:PALI) by 25.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,928,149 shares of the company’s stock after selling 3,121,851 shares during the period. Perceptive Advisors LLC owned 0.05% of Palisade Bio worth $15,624,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. XTX Topco Ltd increased its holdings in Palisade Bio by 53.8% in the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after acquiring an additional 7,584 shares during the last quarter. Cetera Investment Advisers purchased a new stake in Palisade Bio during the fourth quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in Palisade Bio during the fourth quarter valued at about $26,000. Virtu Financial LLC bought a new position in Palisade Bio during the fourth quarter worth about $28,000. Finally, Atom Investors LP bought a new position in Palisade Bio during the fourth quarter worth about $33,000. Institutional investors own 11.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PALI. Weiss Ratings downgraded shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Wolfe Research assumed coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target on the stock. Oppenheimer began coverage on shares of Palisade Bio in a report on Thursday, July 23rd. They issued an “outperform” rating and a $8.00 price objective for the company. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Palisade Bio currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Palisade Bio Stock Down 3.3%

PALI stock opened at $1.90 on Friday. The stock has a 50-day simple moving average of $1.93 and a two-hundred day simple moving average of $1.90. Palisade Bio, Inc. has a twelve month low of $0.53 and a twelve month high of $2.85. The firm has a market capitalization of $328.93 million, a PE ratio of -1.88 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, equities research analysts anticipate that Palisade Bio, Inc. will post -0.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO John David Finley sold 146,798 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total transaction of $303,871.86. Following the completion of the transaction, the chief executive officer directly owned 217,555 shares in the company, valued at $450,338.85. The trade was a 40.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera purchased 25,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was purchased at an average cost of $1.96 per share, for a total transaction of $49,000.00. Following the acquisition, the director owned 461,904 shares of the company’s stock, valued at approximately $905,331.84. This trade represents a 5.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 125,000 shares of company stock worth $250,100 in the last three months. 0.07% of the stock is currently owned by corporate insiders.

Palisade Bio Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.